Discontinued — last reported Q1 '18
Allowance for Doubtful Accounts Receivable (Current)
Pfizer Allowance for Doubtful Accounts Receivable (Current) decreased by 1.1% to $434.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 6.7%, from $465.00M to $434.00M. Over 4 years (FY 2020 to FY 2024), Allowance for Doubtful Accounts Receivable (Current) shows a downward trend with a -3.6% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
A significant increase relative to receivables may signal deteriorating customer credit quality or economic headwinds in specific markets.
Detailed definition
This is a contra-asset account representing the estimated amount of accounts receivable that the company expects will no...
Peer comparison
Standard across all industries; peers in the medical device sector typically maintain low levels unless operating in high-risk emerging markets.
allowance_for_doubtful_accounts_receivable_currentHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $500.00M | $494.00M | $492.00M | $492.00M | $461.00M | $474.00M | $449.00M | $465.00M | $471.00M | $465.00M | $470.00M | $479.00M | $468.00M | $465.00M | $438.00M | $427.00M | $439.00M | $434.00M |
| QoQ Change | — | -1.2% | -0.4% | +0.0% | -6.3% | +2.8% | -5.3% | +3.6% | +1.3% | -1.3% | +1.1% | +1.9% | -2.3% | -0.6% | -5.8% | -2.5% | +2.8% | -1.1% |
| YoY Change | — | — | — | — | -7.8% | -4.0% | -8.7% | -5.5% | +2.2% | -1.9% | +4.7% | +3.0% | -0.6% | +0.0% | -6.8% | -10.9% | -6.2% | -6.7% |
Allowance for Doubtful Accounts Receivable (Current) at Other Companies
Frequently Asked Questions
- What is Pfizer's allowance for doubtful accounts receivable (current)?
- Pfizer (PFE) reported allowance for doubtful accounts receivable (current) of $434.00M in Q3 2025.
- How has Pfizer's allowance for doubtful accounts receivable (current) changed year-over-year?
- Pfizer's allowance for doubtful accounts receivable (current) decreased by 6.7% year-over-year, from $465.00M to $434.00M.
- What is the long-term trend for Pfizer's allowance for doubtful accounts receivable (current)?
- Over 4 years (2020 to 2024), Pfizer's allowance for doubtful accounts receivable (current) has grown at a -3.6% compound annual growth rate (CAGR), from $508.00M to $438.00M.
- What does allowance for doubtful accounts receivable (current) mean?
- The estimated portion of customer invoices that the company expects will never be paid.